Veien N K, Brodthagen H
Br J Dermatol. 1977 Aug;97(2):213-6. doi: 10.1111/j.1365-2133.1977.tb15068.x.
Sixteen patients with cutaneous sarcoidosis, 15 of whom also had involvement of other organs, were treated with methotrexate (MTX) orally once a week in an open study. The treatment period was from 1 to 72 months (mean 23 months). In 12 patients the skin lesions cleared, and in 3 of 4 patients who had sarcoid uveitis this cleared as well. The chest X-ray of 6 patients showed no corresponding improvement in pulmonary changes or in hilar adenopathy. Ten patients suffered side effects, usually nausea on the day MTX was taken. Two had transiently increased transaminase levels. Treatment was discontinued in 2 patients due to nausea. It is concluded that MTX is a useful alternative to systemically administered glucocorticoids in the treatment of disfiguring cutaneous sarcoidosis and sarcoid uveitis. The effect of MTX on hilar adenopathy and pulmonary sarcoidosis is uncertain.
16例皮肤结节病患者（其中15例还累及其他器官）参与了一项开放研究，接受每周一次口服甲氨蝶呤（MTX）治疗。治疗期为1至72个月（平均23个月）。12例患者的皮肤病变消退，4例结节性葡萄膜炎患者中有3例的葡萄膜炎也消退。6例患者的胸部X线片显示肺部病变或肺门淋巴结肿大无相应改善。10例患者出现副作用，通常在服用MTX当天出现恶心。2例患者转氨酶水平短暂升高。2例患者因恶心而停药。结论是，在治疗毁容性皮肤结节病和结节性葡萄膜炎方面，MTX是全身应用糖皮质激素的一种有用替代药物。MTX对肺门淋巴结肿大和肺部结节病的疗效尚不确定。
